Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.37 |
| ▸ | BACE1 | P56817 | 12/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548366 | 0.91 | BACE1 (0.46) | MAP3K14BACE1CTSD | |
| SCHEMBL4549235 | 0.90 | MAP3K14 (0.40) | MAP3K14BACE1CTSD | |
| SCHEMBL4549224 | 0.89 | BACE1 (0.38) | MAP3K14BACE1GABRA1GABRG2GABRB3 | |
| SCHEMBL8414505 | 0.86 | XDH (0.35) | MAP3K14BACE1 | |
| SCHEMBL7571629 | 0.85 | PGR (0.36) | BACE1CTSD | |
| SCHEMBL7550334 | 0.84 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL4549147 | 0.83 | BACE1 (0.38) | BACE1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7573295 | 0.83 | BACE1 (0.43) | BACE1CTSD | |
| SCHEMBL7559922 | 0.83 | BACE1 (0.36) | BACE1 | |
| SCHEMBL4549159 | 0.82 | BACE1 (0.40) | BACE1GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629155-B2 | Aspartyl protease inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629155-B2 | Aspartyl protease inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | MAP3K14 2607/4885BACE1 3/4885GABRA1 3054/4885 |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | MAP3K14 2607/4885BACE1 3/4885GABRA1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.